Coronavirus Updates

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

IDH-mutated AML: First-line IDH inhibitors, chemo may up remission

Stein EM et al. ASH 2018, Abstract 560

Publish date:: January 31, 2019

Key clinical point: The IDH1 inhibitor ivosidenib and IDH2 inhibitor enasidenib combined with induction and consolidation therapy showed promising efficacy against newly diagnosed acute myeloid leukemia.

Major finding: The 1-year survival rates were greater than 75% for patients with previously untreated acute myeloid leukemia who received either of the IDH-mutated inhibitors.

Study details: An open-label, prospective trial in 153 patients with newly diagnosed acute myeloid leukemia.

Disclosures: The study was funded by Agios Pharmaceuticals and Celgene. Dr. Stein reported consulting with those companies and others.

Read the article here.

Citation:

Stein EM et al. ASH 2018, Abstract 560.

This Week's Must Reads

Many children with COVID-19 present without classic symptoms,

System provides ‘faster, less invasive’ method for breast cancer detection,

Posaconazole prophylaxis was effective in children with ALL undergoing chemotherapy,

Study: Immune checkpoint inhibitors don’t increase risk of death in cancer patients with COVID-19,

How prostate cancer treatments affect quality of life,

Must Reads in AML

Combo drug improves survival in older patients with high-risk/secondary AML,

Venetoclax plus LDAC tops LDAC alone in AML,

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML,

First-in-kind anti-CD47 antibody shows promise for MDS and AML treatment,

VIALE-A confirms survival benefit for venetoclax-azacitidine in hard-to-treat AML,